The medical management of lower urinary tract symptoms and benign prostatic hyperplasia

Urologic Clinics of North America

Volumn 25, Issue 4, 1998, Pages 555-569

  Holtgrewe, H L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; FINASTERIDE; NATURAL PRODUCT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHMA; CARDIOTOXICITY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEADACHE; HEALTH ECONOMICS; HUMAN; MALE; MEDICAL ASSESSMENT; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATISM; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; VERTIGO;

EID: 0031765189     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70047-1     Document Type: Article

References (90)

1. P. Abrams J. Blaivas D. Griffiths The objective evaluation of bladder outlet obstruction (urodynamics) Cockett A. Houry S. Aso Y. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH) 1993 Scientific Communications International Channel Islands 115
2. P. Abrams C.C. Schulman S. Voage Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group Br J Urol 76 1995 325 326
3. P. Abrams M. Speakman M. Stott A dose-ranging study of the efficacy and safety of tamsu-losin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia) Br J Urol 80 1997 587 596
4. American Urological Association Gallup Survey of 1997 1997 American Urological Association Baltimore, MD
5. J.T. Andersen P. Ekman H. Wolf Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group Urology 46 1995 631 637
6. J.T. Andersen J.C. Nickel V.R. Marshall Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia Urology 49 1997 839 845
7. M.J. Barry F.J. Fowler B. Lin The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists J Urol 157 1997 10 15
8. M.J. Barry F.J. Fowler M.P. O'Leary The American Urological Association symptom index for benign prostatic hyperplasia J Urol 148 1992 1549 1557
9. M.J. Barry F.J. Fowler M.P. O'Leary Measuring disease specific health status in men with benign prostatic hyperplasia Med Care 33 suppl 4 1995 AS145 AS155
10. P. Boyle A.L. Gould C.G. Roehrborn Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials Urology 48 1996 398 405
11. T.R. Brooks C. Berman D. Garnes Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors Prostate 9 1986 65
12. J.M. Buzelin E. Fonteyne M. Kantturi Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstructions (symptomatic benign prostatic hyperplasia): The European Tamsulosin Study Group Br J Urol 80 1997 597 605
13. M. Caine S. Perlberg S. Maretyk A placebo-controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction Br J Urol 50 1978 551 554
14. M. Caine A. Pfau S. Perlberg The use of alpha adrenergic blockers in benign prostatic obstruction Br J Urol 48 1976 258 263
15. M. Caine S. Raz M. Ziegler Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck Br J Urol 27 1975 193
16. J.C.C. Carraro J.P. Raynaud G. Koch Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1098 patients Prostate 29 1996 231 240
17. W.J. Catalona Urothelial tumors of the urinary tract Walsh P. Retik A. Stamey T. Campbell's Urology ed 6 1992 WB Saunders Philadelphia 1102
18. T. Chirikos E. Sanford Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia J Urol 155 1996 1311 1316
19. C.R. Chapple L. Baert P. Thind Tamsulosin, 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group Eur Urol 32 1997 462 470
20. C.R. Chapple J.J. Wyndaele J. Nordling Tamsulosin, the first prostate-selective alpha 1A adrenoceptor antagonist: A meta-analysis of two randomized placebo-controlled, multi-center studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group Eur Urol 29 1996 155 167
21. L. Denis J. McConnell O. Yoshida Recommendations of the International Consensus Committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction Denis L. Griffiths K. Khoury S. Proceedings of the 4th International Consultation on BPH, July 2–5, 1997, Paris, France 1998 Scientific Communications International Channel Islands 669 683
22. M.R. Feneley W.D. Dunsmuir J. Pearce Reproductibility of uroflow measurement: Experience during a double blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia Urology 47 1996 658 663
23. J.M. Fitzpatrick J. Braeckman L. Denis The medical management of BPH with agents other than hormones or alpha-blocker Cockett A.T. Aso Y. Khoury S. Murphy G. The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH) 1995 Scientific Communications International Channel Islands 489
24. W.F. Gee H.L. Holtgrewe P.C. Albertsen Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States J Urol 154 1995 205 206
25. G.S. Gerber J.H. Kim B.A. Contreras An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin Urology 47 1996 840 844
26. C.J. Girman S.J. Jacobsen H.A. Guess Natural history of prostatism: Relationship among symptoms, prostate volume and peak urinary flow rate J Urol 153 1995 1510 1515
27. C.J. Gormley E. Stoner R.C. Bruskewitz The effect of finasteride in men with benign prostatic hyperplasia N Engl J Med 327 1992 1185 1191
28. H.A. Guess G.J. Gormley E. Stoner The effect of finasteride on prostate specific antigen: Review of available data J Urol 155 1996 3 9
29. Health Care Financing Administration: BESS Data. Washington, DC, 1996.
30. A.L. Hillman J.S. Schwartz M.K. William The cost effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia Urology 47 1996 169 178
31. H.L. Holtgrewe The economics of BPH Cockett A. Aso Y. Chatelain C. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH) 1993 Scientific Communications International Channel Islands 37
32. H.L. Holtgrewe H. Bay-Nielsen C. Bouffioux The economics of prostate cancer Murphy G. Denis L. Chatelain C. Proceedings of the 1st International Consultation on Prostate Cancer, June 20–22, 1996, Monaco 1996 Scientific Communications International Channel Islands 399
33. H.L. Holtgrewe H. Bay-Nielsen P. Carlsson The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia Denis L. Griffiths K. Khoury S. Proceedings of the 4th International Consultation on BPH, July 2–5, 1997, Paris, France 1998 Scientific Communications International Channel Islands 63 81
34. H.L. Holtgrewe W. Mebust J. Dowd Transurethral prostatectomy: Practice aspects of the dominant operation in American urology J Urol 141 1989 248 253
35. IMS Midas 1997 Methodology, on file at Merck, Whitehouse Station, NJ
36. S.J. Jacobsen C.J. Girman J.A. Guess Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men J Urol 155 1996 595
37. R.S. Kirby Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men Urology 46 1995 182 186
38. E. Lee C. Lee Clinical comparison of selective and non-selective alpha 1A adrenoceptors antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses Br J Urol 80 1997 606 611
39. H. Lepor Alpha blockade for the treatment of benign prostatic hyperplasia Urol Clin North Am 22 2 1995 375
40. H. Lepor Long term efficacy and safety of terazosin in patients with benign prostatic hyperplasia: Terazosin Research Group Urology 45 1995 406 413
41. H. Lepor M. Baumann E. Shapiro The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain J Urol 140 1988 644 667
42. H. Lepor C. Dixon K. Slawin BPH—a glimpse into the future AUA News 2 6 1997 12 14
43. H. Lepor D. Guys M. Baumann Laboratory assessment of terazosin and alpha 1 blockade in prostatic hyperplasia Urology 32 suppl 1988 21 26
44. H. Lepor S.A. Kaplan I. Klinberg Doxazosin for benign prostatic hyperplasia: Long term efficacy and safety in hypertensive and normotensive patients J Urol 157 1997 525 550
45. H. Lepor A. Nieder J. Feser Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates Urology 49 1997 476 480
46. H. Lepor E. Shapiro Characterization of the alpha 1 adrenergic receptors in human benign prostatic hyperplasia J Urol 132 1994 1226 1229
47. H. Lepor W.O. Williford M.J. Barry The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia: Veterans Affairs Cooperative Studies N Engl J Med 335 1996 533 539
48. F.C. Lowe Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect Clin Ther 19 1997 730 742
49. F.C. Lowe Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis Urology 44 1994 46 51
50. L.S. Marks A.W. Partin C.J. Gormley Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia J Urol 157 1997 2171 2178
51. H. Matzkin M. Barak Z. Braf Effect of finasteride on free and total serum prostatic specific antigen in men with benign prostatic hyperplasia Br J Urol 78 1996 405 408
52. J.D. McConnell Why pressure flow studies should be optional and not mandatory for evaluating men with benign prostatic hyperplasia Urology 44 1994 156 158
53. J. McConnell M. Barry R. Bruskewitz Benign prostatic hyperplasia: Diagnosis and Treatment Clinical Guidelines, Number 8. AHCPR Publications No. 94-0582 1994 Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services Rockville, MD
54. J.D. McConnell R. Bruskewitc P. Walsh Finasteride decreases the incidence of BPH related surgery and acute urinary retention N Engl J Med 338 1998 557 563
55. J. McConnell J. Wilson F. Geroge Finasteride, an inhibitor of 5 alpha reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia J Clin Endocrinol 73 1992 505 508
56. W. Mebust H.L. Holtgrewe A. Cockett Transurethral prostatectomy: Evaluating 3885 patients J Urol 141 1989 243 247
57. W. Mebust R. Roizo M. O'Leary Correlations between pathology, clinical symptoms and the course of the disease Cockett A. Khoury S. Aso Y. The Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH) 1991 Scientific Communications International Channel Islands
58. R. Montironi M. Valli G. Fabris Treatment of benign prostatic hyperplasia with 5 alpha reductase inhibitor: Morphological changes in patients who fail to respond J Clin Pathol 49 1996 324 328
59. E. Moore B. Bracken W. Bremmer Proscar: Five year experience Eur Urol 28 1995 304 309
60. P. Narayan A. Tewari G. Jacob Differential suppression of serum prostatic acid phosphatase and prostate specific antigen by 5 alpha-reductase inhibitor Br J Urol 75 1995 642 646
61. J.C. Nickel Y. Fradet R.C. Boake Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2 year randomized controlled trial (The PROSPECT Study). PROscar Safety Plans Efficacy Canadian Two Year Study Can Med Assoc J 155 1996 1251 1259
62. J.E. Oesterling J. Roy Agha A. Finasteride PSA Study Group Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride Urology 50 1997 13 18
63. D.K. Ornstein S.R. Garresh D.S. Smith The impact of systemic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate J Urol 157 1997 880 884
64. P.S. Puchner M.I. Miller The effects of finasteride on hematuria associated with benign prostatic hyperplasia: A preliminary report J Urol 154 1995 1779 1782
65. J.M. Reynard T.J. Peters C. Linn The value of multiple free flow studies in men with lower urinary tract symptoms Br J Urol 77 1996 813 818
66. L. Rhodes R.L. Primica C. Berman Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition Prostate 22 1993 43 51
67. R.S. Rittmaster R.W. Norman L.N. Thomas Evidence of atrophy and apoptosis in the prostate of men given finasteride J Clin Endocrinol Metab 81 1996 814 819
68. R.S. Rittmaster E. Stoner D.L. Thompson Effect of MK-906, a specific 5 alpha reductase inhibitor on serum androgens and androgen conjugates in normal men J Androl 10 1989 259 262
69. C.G. Roehrborn H.K. Chinon P.F. Fulghorn The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy J Urol 135 1986 1190 1193
70. C.G. Roehrborn J.E. Oesterling S. Auerbach The Hytrin Community Assessment Trial Study: A one year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group Urology 47 1996 159 168
71. C.G. Roehrborn R.L. Siegel Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double blind, placebo-controlled studies Urology 48 1996 406 415
72. M.G. Sanda B.C. Doehring B. Binkowitz Clinical and biological characteristics of familial benign prostatic hyperplasia J Urol 157 1997 876 902
73. E. Shapiro M.J. Becich H. Lepor The relative proportion of stroma and epithelial hyperplasia is related to the development of clinical BPH J Urol 147 1992 1293
74. E. Shapiro V. Hartonto H. Lepor Quantifying the smooth muscle content of the prostate using double immunoenzymatic staining and color assisted image analysis J Urol 147 1992 1167 1170
75. E. Shapiro V. Hartonto H. Lepor The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle Prostate 21 1992 297 307
76. E. Shapiro H. Lepor Alpha 1 adrenergic receptors in canine lower genitourinary tissues: Insight into development and function J Urol 138 1987 979 983
77. E. Shapiro H. Lepor Pathophysiology of clinical benign prostatic hyperplasia Urol Clin North Am 22 2 1995 285
78. E. Stoner Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia: The Finasteride Study Group Arch Intern Med 154 1994 83 88
79. E. Stoner Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia Urology 43 1994 284 292
80. E. Stoner H. Gregg J. Otterbein Administration of MK-906, a 4 azasteroid compound results in marked suppression of serum dihydrotestosterone in healthy men [abstract] Clin Res 35 1987 402A
81. G. Strauch P. Perles G. Vergult Comparison of finasteride (Proscar) and serenoa repens (Permixon) in the inhibition of 5 alpha reductase in healthy male volunteers Eur Urol 26 1994 247 252
82. T.L. Tammela M.J. Dontturi Long term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia J Urol 154 1995 1466 1469
83. A. Tewari K. Sinohara P. Narayan Transition zone volume and transition zone ratio: Predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients Urology 45 1995 258 264
84. S.R. Tollin H.N. Rosen K. Zurowski Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia—a Clinical Research Center Study J Clin Endocrinol 81 1996 1031 1040
85. U S Decennial Life Tables, State Life Tables V. 1 ALMO 2MT-WY. Life expectancy; mortality (U S) PHS 90-1151 1990 U S Department of Health and Human Services, Public Health Service, National Center for Health Statistics Hyattsville, MD
86. P.C. Walsh J.D. Madden M.J. Harrod Familial incomplete male pseudohermaphroditism, type 2: Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias N Engl J Med 291 1974 944 949
87. J. Wasson D.J. Reda R.C. Bruskewitz A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia: The Veterans Affairs Cooperative Study Group on transurethral resection of the prostate N Engl J Med 332 1995 75 79
88. L. Wilton G. Pearce L. Edet The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,772 patients Br J Urol 78 1996 379 384
89. W.P. Witjes P.F. Rosier C.T. Caris Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder neck obstruction Urology 49 1997 197 205
90. W.P. Witjes F.W. Rosier deWilt M.J. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia J Urol 155 1996 1117 1123